| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.15 | 0.008 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.009 |